Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Description

List of Tables

Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including impaired attention, memory, and executive functions). As a result, schizophrenic patients commonly experience impairments in social and occupational functioning. The management of schizophrenia is challenging due to its clinical and genetic heterogeneity, which also complicates the elucidation of etiological and pathophysiological factors.

The schizophrenia market in the 7MM was valued at $9.0B in the 2021 baseline year. GlobalData anticipates that over the 10-year forecast period, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.7%, reaching $13.0B by 2031.

The major driver for this growth will be the launch of 11 new pipeline products, each of which will have a higher annual cost of therapy (ACOT) when compared with the cost of the most commonly used antipsychotic treatments, which are highly genericized.

Key Highlights

There is an increase in the diagnosed prevalent cases of schizophrenia by 2.6% in the 7MM combined over the forecast period.
The current schizophrenia treatment landscape includes many established atypical antipsychotic products that can help manage the positive symptoms of the disorder, such as hallucinations, delusions, and disorganized speech.
The schizophrenia market will exhibit moderate growth between 2021 and 2031, driven by the entry of 11 pipeline agents.
The potential for novel pharmacological therapies specifically indicated for cognitive impairment associated with schizophrenia (CIAS) and the negative symptoms of schizophrenia, two major unmet needs in the market, could provide new options for patients.
The prospect of four novel adjunctive therapies will be welcomed for patients who have a partial response to marketed antipsychotics. Rather than compete with existing therapies, adjunctive therapies will be prescribed in combination with generic antipsychotics.

Key Questions Answered

What are the key schizophrenia treatments available in 2021?
When will the late stage pipeline products launch, and how will they affect drug sales and the overall schizophrenia market in the 7MM?
Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

Overview of schizophrenia, including epidemiology, symptoms, diagnosis, and disease management.
Annualized schizophrenia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the schizophrenia therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for schizophrenia treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global schizophrenia therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC249PIDR

1 Schizophrenia: Executive Summary

1.1 The schizophrenia market will grow to $13.0 billion
1.2 Key players will struggle to maintain their competitive position
1.3 While outlook in schizophrenia improves, opportunities remain to improve patient outcomes
1.4 The entry of adjunctive therapies will shape the schizophrenia market
1.5 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
- 4.4.1 Sources used
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: 12-month total prevalent cases of schizophrenia
4.5 Epidemiological Forecast for Schizophrenia (2021-31)
- 4.5.1 12-Month total prevalent cases of schizophrenia
- 4.5.2 12-Month diagnosed prevalent cases of schizophrenia
- 4.5.3 Age-specific 12-month diagnosed prevalent cases of schizophrenia
- 4.5.4 Sex-specific 12-month diagnosed prevalent cases of schizophrenia
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 Impact
- 4.6.3 Limitations of Analysis
- 4.6.4 Strengths of Analysis

5 Disease Management

5.1 Diagnosis overview
5.2 Treatment overview
5.3 Other KOL insights on disease management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Development of therapies to target cognitive impairment associated with schizophrenia
7.3 Development of therapies to target negative symptoms
7.4 Development of therapies for treatment-resistant patients
7.5 Improved patient insight and adherence to treatment

8 R&D Strategies

8.1 Overview
- 8.1.1 Reformulations and innovative drug delivery systems
- 8.1.2 Novel MOAs
- 8.1.3 Development of adjunctive therapies
- 8.1.4 Digital therapeutics
8.2 Clinical trial design
- 8.2.1 Clinical endpoints
- 8.2.2 Patient Recruitment

9 Pipeline Assessment

9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

13 Appendix

Product Code: GDHC249PIDR

List of Tables

Table 1: Schizophrenia: Key metrics in the 7MM
Table 2: Risk factors and comorbid conditions associated with schizophrenia
Table 3: Treatment Guidelines for Schizophrenia
Table 4: Schizophrenia market - global drivers and barriers, 2021-2031
Table 5: Key events impacting sales for schizophrenia in the US, 2021-2031
Table 6: Schizophrenia Market - Drivers and Barriers in the US, 2021-2031
Table 7: Key events impacting sales for schizophrenia in the 5EU, 2021-2031
Table 8: Schizophrenia market - drivers and barriers in the 5EU, 2021-2031
Table 9: Key Events Impacting Sales for Schizophrenia in Japan, 2021-2031
Table 10: Schizophrenia Market - Drivers and Barriers in Japan, 2021-2031
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global sales forecast by country for schizophrenia in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in schizophrenia during the forecast period
Figure 3: Competitive assessment of novel oral atypical antipsychotic pipeline agents that GlobalData expects to be licensed for the treatment of schizophrenia during the forecast period
Figure 4: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna
Figure 5: 7MM, 12-month total prevalence (%) of schizophrenia, both sexes, ages ≥13 years, 2021
Figure 6: 7MM, 12-month diagnosed prevalence (%) of schizophrenia, men and women, ages ≥13 years, 2021
Figure 7: 7MM, sources used to forecast the 12-month total prevalent cases of schizophrenia
Figure 8: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of schizophrenia
Figure 9: 7MM, 12-month total prevalent cases of schizophrenia, N, both sexes, ages ≥13 years, 2021
Figure 10: 7MM, 12-month diagnosed prevalent cases of schizophrenia, N, both sexes, ages ≥13 years, 2021
Figure 11: 7MM, 12-month diagnosed prevalent cases of schizophrenia by age, N, both sexes, 2021
Figure 12: 7MM, 12-month diagnosed prevalent cases of schizophrenia by sex, N, ages ≥13 years, 2021
Figure 13: Unmet needs and opportunities in schizophrenia
Figure 14: Overview of the development pipeline in schizophrenia
Figure 15: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for schizophrenia in the 7MM during the forecast period
Figure 16: Competitive assessment of novel oral atypical antipsychotic pipeline drugs benchmarked against the SOC, Abilify
Figure 17: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna
Figure 18: Analysis of the company portfolio gap in schizophrenia during the forecast period
Figure 19: Global (7MM) sales forecast by country for schizophrenia in 2021 and 2031
Figure 20: Sales forecast by class for schizophrenia in the 7MM in 2021 and 2031
Figure 21: Sales forecast by class for schizophrenia in the US in 2021 and 2031
Figure 22: Sales forecast by class for schizophrenia in the 5EU in 2021 and 2031
Figure 23: Sales forecast by class for schizophrenia in Japan in 2021 and 2031

Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Description

Table of Contents

List of Tables

Key Highlights

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Schizophrenia: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Tables

List of Tables

List of Figures

List of Figures